Literature DB >> 31901078

14-3-3 proteins protect AMPK-phosphorylated ten-eleven translocation-2 (TET2) from PP2A-mediated dephosphorylation.

Anirban Kundu1, Sandeep Shelar1, Arindam P Ghosh1, Mary Ballestas2, Richard Kirkman1, Hyeyoung Nam1, Garrett J Brinkley1, Suman Karki1, James A Mobley3, Sejong Bae4, Sooryanarayana Varambally5, Sunil Sudarshan6.   

Abstract

Ten-eleven translocation-2 (TET2) is a member of the methylcytosine dioxygenase family of enzymes and has been implicated in cancer and aging because of its role as a global epigenetic modifier. TET2 has a large N-terminal domain and a catalytic C-terminal region. Previous reports have demonstrated that the TET2 catalytic domain remains active independently of the N-terminal domain. As such, the function of the N terminus of this large protein remains poorly characterized. Here, using yeast two-hybrid screening, co-immunoprecipitation, and several biochemical assays, we found that several isoforms of the 14-3-3 family of proteins bind TET2. 14-3-3 proteins bound TET2 when it was phosphorylated at Ser-99. In particular, we observed that AMP-activated protein kinase-mediated phosphorylation at Ser-99 promotes TET2 stability and increases global DNA 5-hydroxymethylcytosine levels. The interaction of 14-3-3 proteins with TET2 protected the Ser-99 phosphorylation, and disruption of this interaction both reduced TET2 phosphorylation and decreased TET2 stability. Furthermore, we noted that protein phosphatase 2A can interact with TET2 and dephosphorylate Ser-99. Collectively, these results provide detailed insights into the role of the TET2 N-terminal domain in TET2 regulation. Moreover, they reveal the dynamic nature of TET2 protein regulation that could have therapeutic implications for disease states resulting from reduced TET2 levels or activity.

Entities:  

Keywords:  14-3-3; 5-hydroxymethylcytosine (5hmC); AMP-activated protein kinase (AMPK); Post-translational modification; dioxygenase; epigenetics; gene regulation; phosphorylation; protein phosphatase 2A (PP2A); ten-eleven-translocation-2 (TET2)

Mesh:

Substances:

Year:  2020        PMID: 31901078      PMCID: PMC7008385          DOI: 10.1074/jbc.RA119.011089

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display.

Authors:  B Wang; H Yang; Y C Liu; T Jelinek; L Zhang; E Ruoslahti; H Fu
Journal:  Biochemistry       Date:  1999-09-21       Impact factor: 3.162

2.  Phospho-specific binding of 14-3-3 proteins to phosphatidylinositol 4-kinase III beta protects from dephosphorylation and stabilizes lipid kinase activity.

Authors:  Angelika Hausser; Gisela Link; Miriam Hoene; Chiara Russo; Olaf Selchow; Klaus Pfizenmaier
Journal:  J Cell Sci       Date:  2006-08-15       Impact factor: 5.285

3.  Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation.

Authors:  B E Clurman; R J Sheaff; K Thress; M Groudine; J M Roberts
Journal:  Genes Dev       Date:  1996-08-15       Impact factor: 11.361

Review 4.  Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.

Authors:  Parthasarathy Seshacharyulu; Poomy Pandey; Kaustubh Datta; Surinder K Batra
Journal:  Cancer Lett       Date:  2013-02-20       Impact factor: 8.679

5.  Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine.

Authors:  A J Muslin; J W Tanner; P M Allen; A S Shaw
Journal:  Cell       Date:  1996-03-22       Impact factor: 41.582

6.  Fusicoccin signaling reveals 14-3-3 protein function as a novel step in left-right patterning during amphibian embryogenesis.

Authors:  Tom D Bunney; Albertus H De Boer; Michael Levin
Journal:  Development       Date:  2003-08-20       Impact factor: 6.868

Review 7.  14-3-3 and its binding partners are regulators of protein-protein interactions during spermatogenesis.

Authors:  Shengyi Sun; Elissa W P Wong; Michelle W M Li; Will M Lee; C Yan Cheng
Journal:  J Endocrinol       Date:  2009-04-14       Impact factor: 4.286

8.  TET2 stabilization by 14-3-3 binding to the phosphorylated Serine 99 is deregulated by mutations in cancer.

Authors:  Hao Chen; Dingdang Yu; Rui Fang; Kimberlie Rabidou; Di Wu; Di Hu; Peilin Jia; Zhongming Zhao; Zhiping Wu; Junmin Peng; Yang Shi; Yujiang Geno Shi
Journal:  Cell Res       Date:  2019-01-03       Impact factor: 25.617

9.  TET2 binds the androgen receptor and loss is associated with prostate cancer.

Authors:  M L Nickerson; S Das; K M Im; S Turan; S I Berndt; H Li; H Lou; S A Brodie; J N Billaud; T Zhang; A J Bouk; D Butcher; Z Wang; L Sun; K Misner; W Tan; A Esnakula; D Esposito; W Y Huang; R N Hoover; M A Tucker; J R Keller; J Boland; K Brown; S K Anderson; L E Moore; W B Isaacs; S J Chanock; M Yeager; M Dean; T Andresson
Journal:  Oncogene       Date:  2016-11-07       Impact factor: 9.867

10.  Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer.

Authors:  Di Wu; Di Hu; Hao Chen; Guoming Shi; Irfete S Fetahu; Feizhen Wu; Kimberlie Rabidou; Rui Fang; Li Tan; Shuyun Xu; Hang Liu; Christian Argueta; Lei Zhang; Fei Mao; Guoquan Yan; Jiajia Chen; Zhaoru Dong; Ruitu Lv; Yufei Xu; Mei Wang; Yong Ye; Shike Zhang; Danielle Duquette; Songmei Geng; Clark Yin; Christine Guo Lian; George F Murphy; Gail K Adler; Rajesh Garg; Lydia Lynch; Pengyuan Yang; Yiming Li; Fei Lan; Jia Fan; Yang Shi; Yujiang Geno Shi
Journal:  Nature       Date:  2018-07-18       Impact factor: 49.962

View more
  11 in total

Review 1.  AMPK: restoring metabolic homeostasis over space and time.

Authors:  Elijah Trefts; Reuben J Shaw
Journal:  Mol Cell       Date:  2021-09-16       Impact factor: 19.328

Review 2.  Mechanisms that regulate the activities of TET proteins.

Authors:  Kanak Joshi; Shanhui Liu; Peter Breslin S J; Jiwang Zhang
Journal:  Cell Mol Life Sci       Date:  2022-06-15       Impact factor: 9.207

Review 3.  TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics.

Authors:  Yihong Guan; Metis Hasipek; Anand D Tiwari; Jaroslaw P Maciejewski; Babal K Jha
Journal:  Semin Hematol       Date:  2020-12-28       Impact factor: 3.851

Review 4.  The Role of Host Cell DNA Methylation in the Immune Response to Bacterial Infection.

Authors:  Wanhai Qin; Brendon P Scicluna; Tom van der Poll
Journal:  Front Immunol       Date:  2021-07-29       Impact factor: 7.561

5.  USP15 suppresses tumor immunity via deubiquitylation and inactivation of TET2.

Authors:  Lei-Lei Chen; Matthew D Smith; Lei Lv; Tadashi Nakagawa; Zhijun Li; Shao-Cong Sun; Nicholas G Brown; Yue Xiong; Yan-Ping Xu
Journal:  Sci Adv       Date:  2020-09-18       Impact factor: 14.136

Review 6.  Dysregulated TET Family Genes and Aberrant 5mC Oxidation in Breast Cancer: Causes and Consequences.

Authors:  Bo Xu; Hao Wang; Li Tan
Journal:  Cancers (Basel)       Date:  2021-11-30       Impact factor: 6.639

Review 7.  The function and regulation of TET2 in innate immunity and inflammation.

Authors:  Boyi Cong; Qian Zhang; Xuetao Cao
Journal:  Protein Cell       Date:  2020-10-21       Impact factor: 14.870

8.  Small Heat Shock Protein 22 Improves Cognition and Learning in the Tauopathic Brain.

Authors:  Santiago Rodriguez Ospina; Danielle M Blazier; Marangelie Criado-Marrero; Lauren A Gould; Niat T Gebru; David Beaulieu-Abdelahad; Xinming Wang; Elizabeth Remily-Wood; Dale Chaput; Stanley Stevens; Vladimir N Uversky; Paula C Bickford; Chad A Dickey; Laura J Blair
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

9.  The TGF-β/HDAC7 axis suppresses TCA cycle metabolism in renal cancer.

Authors:  Hyeyoung Nam; Anirban Kundu; Suman Karki; Garrett J Brinkley; Darshan S Chandrashekar; Richard L Kirkman; Juan Liu; Maria V Liberti; Jason W Locasale; Tanecia Mitchell; Sooryanarayana Varambally; Sunil Sudarshan
Journal:  JCI Insight       Date:  2021-11-22

10.  PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen.

Authors:  Samantha L Tinsley; Brittany L Allen-Petersen
Journal:  NAR Cancer       Date:  2022-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.